Regeneron Investor Event (ESMO) Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Tyler Van Buren - TD Cowen - Analyst : Hey, guys. Thanks very much for the presentations. You guys are doing a lot of great work in oncology. So I wanted to ask about Fianlimab again, given the data of Fianlimab and Libtayo melanoma, I'd be shocked if the Phase 3 next year was not successful. So perhaps we could talk about the market a bit. What percent of the frontline melanoma market, do you believe a LAG-3 I-O combo could take and do observations with the ongoing up to a lag launch support that so far?

Question: Chris Schott - JPMorgan - Analyst : Great. Thanks so much. Just maybe pivoting over to the BCMA bispecific, can you just elaborate how you are you thinking about competitive dynamics here over time? Seems like some of your competitors are evolving their dosing profiles. I'm just wondering just your thoughts on -- do we end up with the various (inaudible) market end up with dosing and hospitalization that maybe looks more similar when different to one another. And how do you think about that would mean competitively? Thank you.

Question: Mohit Bansal - Wells Fargo - Analyst : Thank Izzy. Kevin let's go to one more question, please.

Question: Terence Flynn - Morgan Stanley - Analyst : Great. Thanks for taking the question, and thanks for the overview. Obviously, there's been a lot of excitement over the last several months on PD-1 VEGF bispecifics. I know you guys have a different type of bispecific platform, but just wondering if that's something REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 16, 2024 / 12:30PM, REGN.OQ - Regeneron Investor Event (ESMO) you've looked at all. And any of your animal models, if that's something you're considering? And then what are the implications as you think about kind of future lung cancer market? Thank you.

Question: Mohit Bansal - Wells Fargo - Analyst : Thank you for squeezing me. And going back to the lag data. So I just -- like what could be your rational behind that combination, not working -- less than 1% PD-1 patients. Is it down to PD-1 there? And in that regard, your combination could be better because more and more you look at the data, Libtayo seems more likely to (inaudible) any other agent that is out there.

Question: Mohit Bansal - Wells Fargo - Analyst : Sure. I can repeat it. So the question is for lag, what would be the -- like when you look at the data, what is your internal thinking about why this drug did not buzz among the less than 1% PD-L1 patients. Is it down to the checkpoint inhibitor or a PD-1 inhibitor here? And to that point, do you think your combination may have a better shot at that particular subgroup of the patient, given that your PD-1 seems more similar to a Keytruda rather than nivolumab. Thank you.